Share:
Assisted psychedelic treatment executives came together at the two-day, virtual Benzinga Global Small Cap Conference on Thursday to discuss recent lab developments and the significant hurdles ahead in mental health and addiction treatment.
Forbes Will Yakowicz moderated the digital panel featuring:
Joshua Bartch, CEO and co-founder,
Mydecine Innovations Group Inc (Pink: MYCOF)
Doug Drysdale, CEO,
Payton Nyquvest, chairman & CEO,
Numinus Wellness Inc (Pink: LKYSF)
There is a need for a paradigm shift in mental health treatment and psychedelics could be part of the plan, said Nyquvest. The current landscape of the market is filled with promise but still faces hardships in government approval and patient access, he said.